DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

Information source: University Hospital Case Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Lymphatic Filariasis

Intervention: Diethylcarbamazine (Drug); Albendazole (Drug); Ivermectin (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: University Hospital Case Medical Center

Official(s) and/or principal investigator(s):
Peter Siba, PhD, Principal Investigator, Affiliation: Papua New Guinea Institution for Medical Research

Overall contact:
Christopher L King, MD, PhD, Phone: 4402476904, Email: cxk21@case.edu


This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given to treat this infection. The three drugs used together are called albendazole (ALB), ivermectin (IVM) and diethylcarbamazine (DEC). The usual treatment in Papua New Guinea (PNG) for lymphatic filariasis are DEC and ALB. A combination of these 3 drugs has not been previously used to treat LF.

Clinical Details

Official title: Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Percentage of subjects with total clearance of in Wuchereria bancrofti (Wb) microfilaria (mf)

Detailed description: This will determine whether 1 or 2 annual treatments with the triple drug regimen of DEC/Iver/Alb is equally or more effective than repeated annual treatments with DEC/Alb in inducing sustained clearance of Mf in LF infected subjects previously determined to have >100Mf/ml, indicative of a moderate to heavy infection. Subjects will be treated and monitored in several common areas near study subject residences. There will be 3 treatment arms as follows: 1. The comparator (standard treatment) DEC 6 mg/kg + Alb 400 mg administered annually (at 0, 12, and 24 months). 2. DEC 6 mg/kg + Alb 400 mg given once 3. DEC 6 mg/kg + Alb 400 mg + Iver 200 µg/kg administered once only at the beginning of the RCT (0 month).


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Men and women 18-65 years

- >100mf/ml in finger stick blood samples

- Willing to give informed consent

Exclusion Criteria:

- Prior treatment for LF within last 5 years

- Pregnant (do pregnancy test)

- Hemoglobin < 7 g/dl

- permanent disability, serious medical illness that prevents or impedes study

participation and/or comprehension

- AST/ALT and creatinine > 1. 5 upper limit of normal.

- Urine dipstick with glucose ≥ 2+ and/or protein ≥ 2+

Locations and Contacts

Christopher L King, MD, PhD, Phone: 4402476904, Email: cxk21@case.edu

Papua New Guinean Institute for Medical Research, Maprik, East Sepik, Papua New Guinea; Recruiting
James Suamani, Phone: +675 71066112, Email: jsuamani@gmail.com
Manasseh Baea, Phone: +675 73332320, Email: manasseh.baea@gmail.com
Additional Information

Starting date: October 2013
Last updated: October 28, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017